AGIO
Agios Pharmaceuticals Inc.
$38.19
+$0.49(+1.30%)
67
Overall
80
Value
54
Tech
--
Quality
Market Cap
$2.19B
Volume
437.19K
52W Range
$23.42 - $62.58
Target Price
$49.29
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $59.1M | $69.9M | $43.0M | $94.4M | $117.9M | $121.1M | $500.0K | $14.2M | $26.8M | $36.5M | ||
| Total Revenue | $59.1M | $69.9M | $43.0M | $94.4M | $117.9M | $203.2M | $500.0K | $14.2M | $26.8M | $36.5M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $-135.0K | $-70.0K | -- | $-1.4M | $1.3M | $-2.8M | -- | $1.7M | $2.9M | $4.2M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $59.1M | $69.9M | $43.0M | $93.0M | $116.6M | $200.4M | $500.0K | $12.5M | $23.9M | $32.3M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-177.8M | $-270.9M | $-363.8M | $455.5M | $542.9M | $335.9M | $378.4M | $401.6M | $415.4M | $458.1M | ||
| Research & Development | $141.8M | $220.2M | $292.7M | $341.3M | $410.9M | $220.8M | $257.0M | $279.9M | $295.5M | $301.3M | ||
| Research Expense | $141.8M | $220.2M | $292.7M | $341.3M | $410.9M | $220.8M | $257.0M | $279.9M | $295.5M | $301.3M | ||
| Selling, General & Administrative | $36.0M | $50.7M | $71.1M | $114.1M | $132.0M | $115.1M | $121.4M | $121.7M | $119.9M | $156.8M | ||
| Selling & Marketing Expenses | -- | -- | $71.1M | $114.1M | -- | $149.1M | -- | -- | -- | -- | ||
| General & Administrative Expenses | $36.0M | $50.7M | $-6.0M | $-11.4M | $132.0M | $115.1M | $121.4M | $121.7M | $119.9M | $156.8M | ||
| Salaries & Wages | $-32.0M | $-42.1M | $-47.8M | $-73.4M | -- | $-75.1M | -- | -- | -- | -- | ||
| Depreciation & Amortization | $-3.3M | $-5.7M | $-6.4M | $-7.2M | $8.0M | $9.4M | $8.8M | $8.4M | $6.6M | $5.7M | ||
| Depreciation & Amortization | $-3.3M | $-5.7M | $-6.4M | $-7.2M | $8.0M | $9.4M | $8.8M | $8.4M | $6.6M | $5.7M | ||
| Other Operating Expenses | -- | -- | $-363.8M | $-456.9M | $-3.2M | $-3.7M | $-3.1M | $-2.0M | $-2.4M | $-3.0M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-118.7M | $-201.0M | $-320.8M | $-362.5M | $-426.3M | $-335.9M | $-378.4M | $-389.0M | $-391.5M | $-425.7M | ||
| EBITDA | $-113.9M | $-192.0M | $-308.3M | $-342.7M | $-398.0M | $-326.1M | $-369.2M | $-380.5M | $-334.7M | $735.2M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | -- | -- | $17.8M | -- | -- | -- | -- | ||
| Intinc | $968.0K | $2.5M | $6.1M | $16.5M | $14.9M | $6.6M | $836.0K | $12.8M | $33.3M | $48.1M | ||
| Net Non-Operating Interest Income/Expense | $968.0K | $2.5M | $6.1M | $16.5M | $14.9M | $6.6M | $836.0K | $12.8M | $33.3M | $48.1M | ||
| Gain on Sale of Securities | $-261.0K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Income/Expense | $261.0K | -- | -- | $-37.6M | $-31.6M | $-61.5M | $-21.1M | $144.5M | $-6.1M | $-206.5M | ||
| Other Special Charges | -- | -- | -- | $37.6M | $31.6M | $61.5M | $21.1M | $16.6M | $6.1M | $6.5M | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-117.7M | $-198.5M | $-314.7M | $-346.0M | $-411.5M | $-335.9M | $-378.4M | $-389.0M | $-352.1M | $718.0M | ||
| Pre-Tax Income | $-117.7M | $-198.5M | $-314.7M | $-346.0M | $-411.5M | $-329.3M | $-356.5M | $-231.8M | $-352.1M | $718.0M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | -- | -- | -- | -- | -- | -- | -- | -- | -- | $44.2M | ||
| NET INCOME | ||||||||||||
| Net Income | $-117.7M | $-198.5M | $-314.7M | $-346.0M | $-411.5M | $-327.4M | $1.6B | $-231.8M | $-352.1M | $673.7M | ||
| Net Income (Continuing Operations) | $-117.7M | $-198.5M | $-314.7M | $-346.0M | $-411.5M | $-327.4M | $1.6B | $-231.8M | $-352.1M | $673.7M | ||
| Net Income (Discontinued Operations) | $-117.7M | $-198.5M | $-314.7M | $-346.0M | $-411.5M | $-327.4M | $1.6B | $-231.8M | $-352.1M | $673.7M | ||
| Net Income (Common Stockholders) | $-117.7M | $-198.5M | $-314.7M | $-346.0M | $-411.5M | $-327.4M | $1.6B | $-231.8M | $-352.1M | $673.7M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $510.8M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-178.0M | $-270.9M | $-363.8M | $454.1M | $544.2M | $513.7M | $378.4M | $403.3M | $418.3M | $462.2M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $37.4M | $39.1M | $46.6M | $57.4M | $60.0M | $69.0M | $60.4M | $54.8M | $55.7M | $56.8M | ||
| Average Shares Outstanding (Diluted) | $37.4M | $39.1M | $46.6M | $57.4M | $60.0M | $86.4M | $60.4M | $54.8M | $55.7M | $57.9M | ||
| Shares Outstanding | $37.9M | $42.2M | $57.3M | $58.4M | $68.5M | $69.6M | $54.6M | $55.3M | $56.2M | $57.3M | ||
| Basic EPS | -- | -- | -- | -- | $-6.86 | -- | $53.1 | $-8.46 | $-6.33 | $11.86 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | $-6.86 | -- | $20.65 | $-8.46 | $-12.66 | $11.86 | ||
| Diluted EPS | $-3.15 | $-5.07 | $-6.75 | $-6.03 | $-6.86 | $-4.74 | $53.1 | $-8.46 | $-6.33 | $11.64 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | $20.65 | $-8.46 | $-12.66 | $11.64 | ||
| OTHER METRICS | ||||||||||||
| Basic Discontinuous Operations | -- | -- | -- | -- | -- | -- | $32.45 | -- | -- | -- | ||
| Diluted Discontinuous Operations | -- | -- | -- | -- | -- | -- | $32.45 | -- | -- | -- | ||
| Gain On Sale Of Business | -- | -- | -- | -- | -- | -- | $6.6M | -- | -- | $200.0M | ||
| Net Income Discontinuous Operations | -- | -- | -- | -- | -- | $1.9M | $2.0B | -- | -- | -- | ||
| Net Income From Other Gains Losses | -- | -- | -- | -- | -- | $-17.8M | -- | -- | -- | -- | ||
| Other Gain Loss From Disposition Of Discontinued Operations | -- | -- | -- | -- | -- | $1.9M | $2.0B | -- | -- | -- | ||
| Other Gand A | $36.0M | $50.7M | $-6.0M | $-11.4M | $132.0M | $115.1M | $121.4M | $121.7M | $119.9M | $156.8M | ||
| Rent And Landing Fees | $36.0M | $50.7M | $-6.0M | $-11.4M | -- | -- | -- | -- | -- | -- | ||
| Selling Expense | -- | -- | $71.1M | $114.1M | -- | $149.1M | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AGIO | $38.19 | +1.3% | 437.19K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Agios Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW